Publications

• Bowles EJ, Schiffner T, Rosario M, Needham GA, Ramaswamy M, McGouran J, Kessler B, LaBlanche C, Montefiori D, Sattentau QJ, McMichael AJ, Hanke T and Stewart-Jones GBE. Enhanced potency and breadth of neutralising antibody responses in macaques immunised with polyvalent HIV-1 gp140 protein antigens. PLoS ONE Submitted.
• Clutton G, Bridgeman A, Hanke T and Dorrell L. Transient IL-10 receptor blockade can enhance CD8+ T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen. Vaccine Submitted.
• Ternette N, Yang H, Partridge T, Llano A,Cedeño S, Fischer R, Charles P, Dudek NL, Purcell AW, Borrow P, Mothe B, Crespo M,Dorrell L, Brander C, Kessler BM and Hanke T. Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected cells. Nat Biotechnology Submitted.
• Ondondo B, Abdul-Jawad S, Bridgeman A and Hanke T. Characterization of T-cell responses to conserved regions of the HIV-1 proteome in the BALB/c mice. Clin Vaccine Immunol Submitted.
• Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Hanke T, Mothe B, Brander C, Goonetilleke N, McMichael A, McElrath MJ, Tomaras G, Frahm N, Dorrell L Identification of effective anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoSPathog Submitted.
• Clutton G, Carpov A, Parks CL, Dean HJ, Montefiori DC and Hanke T. Optimizing parallel induction of HIV-1-specific antibody and T-cell responses by multicomponent subunit vaccines. AIDS In press.
• Njuguna IN, Ambler G, Reilly M, Ondondo B,Kanyugo M, Lohman-Payne B, Gichuhi C, Borthwick N, Black A, Mehedi S-R, Maleche-Obimbo E, Chohan B, John-Stewart GC, Jaoko W and Hanke T. PedVacc 002: A phase I randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-infected mothers in Nairobi. Vaccine In press.
• Hayton E-J, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A, Black A, Dorrell L and Hanke T. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus Ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS ONE 9: e101591. eCollection 2014 (2014).
• Saubi N, Gea-Mallorqui E, Hurtado C, Ferrer P, Gatell JM, Hanke T and Joseph J. Engineering new mycobacterial vaccine design forHIV-TB pediatric vaccine vectored by lysine auxotrophof BCG.MolTher Methods ClinDev 1:14017 (2014).
• Hanke T. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin. Biol. Ther. 14: 601-616 (2014).
• Chen L, Fischer R, Peng Y, Reeves E, Ternette N, Hanke T, Dong T, Elliott T, Shastri N, Kollnberger S, James E, Kessler B and Bowness P. Endoplasmic reticulum aminopeptidase 1 (ERAP1) plays a critical role in determining the length and sequence of peptides bound and presented by HLA-B27. Arthritis Rheumatol66: 284-294 (2014).
• Naarding MA, Fernandez N, Kappes JC, Hayes P, Ahmed T, Icyuz M, Edmonds TG, Bergin P, Hanke T, Clark L, Cox JH, Cormier E, Ochsenbauer C and Gilmour J. Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. J Immunol Methods In press (2014).
• Borthwick B, Ahmed T, Ondondo B, Hayes P, Rose A, Ibrahimsa U, Hayton E-J, Black A, Bridgeman A, Rosario M, Hill AVS, Berrie E, Moyle S, Frahm N, Cox J, Colloca S, Nicosia A, Gilmour J, McMichael AJ, Dorrell L and Hanke T. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. MolTher 22:464-475 (2014).
• NjugunaI, Reilly M, Jaoko W, Gichuhi C, Ambler G, Maleche-Obimbo E, Lohman-Payne B, Hanke T and John-Stewart G. Infant neutropenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of HIV. Retrovirology6: 1-5 (2014).
• Afolabi MO, Ndure J, Drammeh A, Darboe F, Mehedi S-R, Borthwick-N, Rowland-Jones S, Black A, Hanke T and Flanagan KL. Phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS ONE 8: e78289. eCollection 2013 (2013).
• Ondondo B, Brennen C, Nicosia A, Crome SJ and Hanke T. Absence of systemic toxicological changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. Vaccine 31: 5594– 5601 (2013).
• Koopman G, Beenhakker N, Nieuwenhuis I, Doxiadis G, Mooij P, Drijfhout JW, Koestler J, Hanke T, Fagrouch Z, Verschoor EJ, Bontrop RE, Wagner R, Bogers WMJM and Melief CJM. DNA/long peptide vaccination against conserved regions of SIV induces protection against high dose intrarectal SIVmac251 challenge. AIDS In press (2013).
• Saubi N, Mbewe-Mvula A, Gea E, Rosario M, Gatell JM, Hanke T and Joseph J. Pre-clinical development of BCG.HIVACAT, an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. PLoS ONE 7: e42559 (2012).
• Roshorm Y, Cottingham M, Potash M-J, Volsky DJ and Hanke T. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens protect against chimeric HIV-1 challenge. Eur J Immunol: 42: 1-13 (2012).
• Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, Bridgeman A, Reyes-Sandoval A, Nicosia A, Ljungberg K, Hanke T, and Liljeström P. Superior induction of T cell responses to conserved HIV-1 regions by electroporatedalphavirus replicon DNA compared to conventional plasmid DNA vaccine. J Virol 86: 4082-4090 (2012).
• Kelschenbach J, Saini JM, Hadas E, Gu C-J, Chao W, Bentsman G, Hong J, Hanke T, Sharer LR, Potash MJ, and Volsky DJ. Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV-1. J NeuroimmunePharmacol 7:380-387 (2012).
• Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mvula A, Bridgeman A, Colloca S, Monefiori D, McMichael AJ, Nicosia A, Drijfhout JW, Melief CJ, and Hanke T. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV in macaques. AIDS 26: 275-284 (2012).
• Hopkins R, Bridgeman A, Bourne C, Mbewe-Mvula A, Sadoff JC, Both GW, Joseph J, Fulkerson J, and Hanke T.Optimizing HIV-1-specific CD8+ T cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 41: 3542-3552 (2011).
• Hanke T, and McMichael AJ. HIV-1: from escapism to conservatism.Eur J Immunol 41: 3390-3393 (2011).
• Joseph J, Saubi N, Im E-J, Fernandez-Lloris R, Gil OL, Cardona P-J, Gatell J-M and Hanke T. J NeuroimmunePharmacol, and. Newborn mice vaccination with rBCG.HIVA222 + MVA.HIVA enhances HIV-1- specific immune responses. Influence of age and immunization routes. Clin Develop Immunol 2011: Article ID 516219, 11 pages (2011).
• Hopkins R, Bridgeman A, Joseph J, Gilbert S, McShane H and Hanke T. Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS ONE 6: e20067 (2011).
• Im E-J, Hong JP, Roshorm Y, Bridgeman A, Létourneau S, Liljeström P, Potash MJ, Volsky DJ, McMichael AJ and Hanke T. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenge. PLoSPathog 7: e1002041 (2011).